Phio Pharmaceuticals Corp... (PHIO)
| Bid | 2.02 |
| Market Cap | 9.75M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -7.15M |
| EPS (ttm) | -9.08 |
| PE Ratio (ttm) | -0.22 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 2.05 |
| Volume | 836,264 |
| Avg. Volume (20D) | 3,211,185 |
| Open | 2.47 |
| Previous Close | 2.51 |
| Day's Range | 2.00 - 2.50 |
| 52-Week Range | 0.97 - 9.79 |
| Beta | 1.08 |
About PHIO
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic pr...
Analyst Forecast
According to 1 analyst ratings, the average rating for PHIO stock is "Buy." The 12-month stock price forecast is $4, which is an increase of 96.08% from the latest price.
Stock Forecasts
2 months ago · newsfilecorp.com
Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of DirectorsMarlborough, Massachusetts--(Newsfile Corp. - February 20, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siR...